Michael Weiss
Chief Executive Officer bei TG THERAPEUTICS, INC.
Vermögen: 202 Mio $ am 31.03.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Lindsay Rosenwald | M | 68 |
Helocyte, Inc.
 Helocyte, Inc. Miscellaneous Commercial ServicesCommercial Services Helocyte, Inc. engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or CMV (cancer and infectious disease). It focuses on developing PepVax, a HLA-restricted single antigen peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant recipients and Triplex. The company was founded by Donald J. Diamond in 2015 and is headquartered in New York, NY.
Baergic Bio, Inc.
 Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY.
Cellvation, Inc.
Cyprium Therapeutics, Inc.
 Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The private company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then. | 28 Jahre |
| Neil Herskowitz | M | 67 | 20 Jahre | |
| James Oliviero | M | 48 |
ACCESS Oncology, Inc.
 ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Part of Akebia Therapeutics, Inc., ACCESS Oncology, Inc. is a private company that develops pharmaceutical drugs. The company is based in New York, NY. The company was founded by Michael Sean Weiss. ACCESS Oncology was acquired by Keryx Biopharmaceuticals, Inc., part of Akebia Therapeutics, Inc. from December 13, 2018 on February 06, 2004 for $36.44 million. | 25 Jahre |
| Frank Taffy | M | - |
Cellvation, Inc.
Helocyte, Inc.
Helocyte, Inc. Miscellaneous Commercial ServicesCommercial Services Helocyte, Inc. engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or CMV (cancer and infectious disease). It focuses on developing PepVax, a HLA-restricted single antigen peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant recipients and Triplex. The company was founded by Donald J. Diamond in 2015 and is headquartered in New York, NY. | 9 Jahre |
| William Gray | M | 36 | 8 Jahre | |
| Adam Chill | M | 56 | 10 Jahre | |
| Jay Kranzler | M | 66 |
Baergic Bio, Inc.
Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY. | 7 Jahre |
| Sean Power | M | 42 | 18 Jahre | |
| Manuel Litchman | M | 70 | 7 Jahre | |
| Xiao Qin Lu | M | 49 | 8 Jahre | |
| Daniel Hume | M | 57 | 9 Jahre | |
| Kenneth Hoberman | M | 59 | 19 Jahre | |
| Lung S. Yam | M | - |
Cyprium Therapeutics, Inc.
Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The private company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then. | 7 Jahre |
| George Avgerinos | M | 71 | 11 Jahre | |
| Malcolm Hoenlein | M | 80 | 17 Jahre | |
| Michael Anthony Mullen | M | 56 | 7 Jahre | |
| Brian Achenbach | M | 59 | 7 Jahre | |
| Sagar Lonial | M | 57 | 4 Jahre | |
| Jaclyn Jaffe | F | - | - | |
| Michael Zelefsky | M | 63 | 7 Jahre | |
| Greg Furrow | M | - | 5 Jahre | |
| Samuel Berry | M | - | 8 Jahre | |
| Kevin Lorenz | M | 59 | 5 Jahre | |
| David Jin | M | 34 | - | |
| Yann Echelard | M | 60 | 12 Jahre | |
| James Murphy | M | 67 | - | |
| Laurence Charney | M | 76 | 12 Jahre | |
| Dov Klein | M | 72 | 9 Jahre | |
| Barry Salzman | M | 62 | 8 Jahre | |
| J. Lobell | M | 61 | 18 Jahre | |
| Jimmie Harvey | M | 72 | 16 Jahre | |
| Jenna A. Bosco | F | - | 13 Jahre | |
| Christian Béchon | M | 63 | 6 Jahre | |
| Michael Ryan | M | - | 6 Jahre | |
| Nicole McCloskey | F | - | - | |
| Robert Sexton | M | - | 2 Jahre | |
| Rick Bodmer | M | - | 2 Jahre | |
| Debra Manning | F | - | 5 Jahre | |
| Eric Rowinsky | M | 67 | 14 Jahre | |
| Lynn E. Bayless | F | - | 4 Jahre | |
| Adam Waldman | M | - | 6 Jahre | |
| Jaclyn Jaffe | F | - | - | |
| Scott A. Reines | M | 77 | 8 Jahre | |
| Bruce Dezube | M | - | 3 Jahre | |
| Peter Carney | M | 38 | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Jose M. Aldeanueva | M | 55 | - | |
| Michael Tarnok | M | 69 | 9 Jahre | |
| Michael G. McGuinness | M | 70 | 5 Jahre | |
| Robert Fagenson | M | 75 | 9 Jahre | |
| Robyn Hunter | F | 62 | 11 Jahre | |
| Harlan Weisman | M | 71 | 1 Jahre | |
| Beth Levine | F | 60 | 1 Jahre | |
| David J. Horin | M | 56 | 2 Jahre | |
| Mark Stier | M | 63 | 1 Jahre | |
| Mark Klein | M | 60 | 3 Jahre | |
| Douglas A. Abel | M | 62 | 6 Jahre | |
| Joseph Vazzano | M | 40 | 5 Jahre | |
| Goldie Goldwasser | M | 64 | 16 Jahre | |
| Michelle Y. Carroll | F | - | - | |
| Jaideep Gogtay | M | 58 | 3 Jahre | |
| Michael Singer | M | 57 | 4 Jahre | |
| Kevin Cameron | M | 64 | 11 Jahre | |
| Jack Kaye | M | 80 | 10 Jahre | |
| Knut Niss | M | - | - | |
| Sadik Kassim | M | - | 2 Jahre | |
| Jeffrey J. Gutovich | M | 67 | - | |
| Jeff Paley | M | 55 | 4 Jahre | |
| David Shimko | M | 63 | 1 Jahre | |
| Nishant Saxena | M | 48 | - | |
| Scott Boilen | M | 57 | 8 Jahre | |
| Paul J. Coviello | M | 70 | 2 Jahre | |
| Alan B. Levin | M | 60 | 8 Jahre | |
| Michael T. Eustace | M | - | 1 Jahre | |
| Jorge A. Ortega | M | 59 | 4 Jahre | |
| Marshall Geller | M | 85 | 6 Jahre | |
| William James Kennedy | M | 79 | 9 Jahre | |
| I. Craig Henderson | M | 82 |
ACCESS Oncology, Inc.
ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Part of Akebia Therapeutics, Inc., ACCESS Oncology, Inc. is a private company that develops pharmaceutical drugs. The company is based in New York, NY. The company was founded by Michael Sean Weiss. ACCESS Oncology was acquired by Keryx Biopharmaceuticals, Inc., part of Akebia Therapeutics, Inc. from December 13, 2018 on February 06, 2004 for $36.44 million. | 7 Jahre |
| H. Laurence Shaw | M | - | - | |
| Eli Salig | M | 74 | 3 Jahre | |
| Nicholas J. Rossettos | M | - | - | |
| Ronald Bentsur | M | 58 | 6 Jahre | |
| Arthur Asher Kornbluth | M | 64 | 2 Jahre | |
| Wyche Fowler | M | 83 | 10 Jahre | |
| Richard Steinhart | M | 66 | 8 Jahre | |
| Stephen B. Pudles | M | 63 | - | |
| Athanassios Michas | M | 79 | 2 Jahre | |
| Michael Rogers | M | 64 | 2 Jahre | |
| Malcolm Morville | M | 78 | - | |
| Morris Laster | M | 60 | 5 Jahre | |
| Mark J. Schoenebaum | M | 51 | 7 Jahre | |
| Akhtar Samad | M | 64 | 4 Jahre | |
| Ronald Renaud | M | 55 | 1 Jahre | |
| Barry Rodgers | M | 84 | - | |
| Matthew Wein, | - | - | - | |
| Alan G. Harris | M | 72 | 1 Jahre | |
| BILL Kessler | M | 57 | 2 Jahre | |
| Leonard M. C. Firestone | M | - | 2 Jahre | |
| Eric Rose | M | 73 | - | |
| Alexandra MacLean | M | 57 | 1 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 95 | 95,96% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Michael Weiss
- Persönliches Netzwerk
